(Q34615632)

3 August 2017

1 reference

title

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development (English)

1 reference

3 August 2017

Suoping Zhai

1

1 reference

3 August 2017

Adrian M Senderowicz

series ordinal

2

1 reference

3 August 2017

Edward A Sausville

series ordinal

3

1 reference

3 August 2017

William D Figg

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Annals of Pharmacotherapy

3 August 2017

1 reference

3 August 2017

36

1 reference

3 August 2017

905-911

1 reference

3 August 2017

5

1 reference

3 August 2017

1 reference

Principles of CDK regulation

21 January 2018

1 reference

Cyclin-dependent kinases: engines, clocks, and microprocessors

21 January 2018

1 reference

Cell cycle control and cancer

21 January 2018

1 reference

Cdk inhibitors in development and cancer

21 January 2018

1 reference

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

21 January 2018

1 reference

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target

21 January 2018

1 reference

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

21 January 2018

1 reference

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

21 January 2018

1 reference

Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity

21 January 2018

1 reference

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

21 January 2018

1 reference

Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release.

21 January 2018

1 reference

High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers

21 January 2018

1 reference

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1A162

1 reference

3 August 2017

1 reference